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Reporting standards for studies involving endovascu-
lar repair of infrarenal abdominal aortic aneurysms were
introduced by the Society for Vascular Surgery in 1997
and revised in 2002.1-3 Although the 2002 standards
addressed endovascular aortic aneurysm repair in a more
general sense, they did not focus on thoracic endografts.
With the development of endovascular grafts to treat
thoracic aortic pathology, there is a need for reporting
standards specific to this procedure. Many of concepts
and definitions of success are extrapolated from the prior
publications regarding standards for endovascular ab-
dominal aortic aneurysm repair (EVAR). Nonetheless,
thoracic endovascular aortic repair (TEVAR) incorpo-
rates some unique aspects, ranging from specific ana-
tomic issues to the differing etiologies of diseases affect-
ing the thoracic aorta, such as dissection, traumatic
injury, penetrating ulcer, and pseudoaneurysm. The
framework for TEVAR reporting will be addressed in this
article. The reporting standards for aortic dissection are
particularly complex and will be addressed in more detail
in a separate publication.
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1022CLASSIFICATION CRITERIA FOR THORACIC
AORTIC PATHOLOGY
Classification of thoracic aortic pathology is recom-
mended with respect to a combination of factors, including
(1) site, (2) etiology, and (3) clinicopathologic manifesta-
tions. In any one specific report, the selection of only one of
these factors as the basis for classification may be appropri-
ate.
Anatomic classification. All reports should classify
aortic aneurysms on the basis of site and extent of disease
(Table I). Classification may require inclusion of multiple
sites, as listed in the table. Notably, the classic definitions of
type I to IV thoracoabdominal aortic aneurysm by Craw-
ford are not consistently interpreted in the literature, partly
because the illustrations from the original articles show the
worst case of the type IV variant.4-9 Reports involving
thoracoabdominal aortic pathology need to use a clear
definition, including the number of branch vessels treated
(if any). Other pathology, such as dissection, penetrating
aortic ulcer, and intramural aortic hematoma, should also
be reported on the basis of site and extent, but penetrating
aortic ulcer and intramural aortic hematoma require addi-
tional information with regard to depth of the ulceration,
thickness of the associated hematoma, and the presence or
absence of symptoms.
One challenging issue with thoracic aortic pathology is
the ability to differentiate penetrating aortic ulcer, intramu-
ral aortic hematoma, dissection, and aneurysm. Clinical
differentiation is further complicated because the diagnosis
is time-dependent as one type of pathology can evolve into
others. Reports should attempt to classify the aortic pathol-
ogy based on the primary process and avoid reports that
group multiple pathologic types without distinction of
etiologies and outcomes. Once a patient’s pathology has
been classified for data collection, it should not appear in
another manuscript under a different classification to avoid
problems with meta-analysis.
In all pathologic entities, the diameter of the aorta is of
interest and should be recorded in a standard fashion.
Given the inherent tortuosity of the thoracic aorta after
pathologic changes have occurred, diameter assessments
unstable, vital signs, associated cardiac arrest
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(on a perpendicular plane) to the centerline of the vessel
using three-dimensional (3-D) reconstructions. For cases
in which a diameter perpendicular to the vessel centerline is
not available, the minor and major axis diameter of the
aneurysm should be recorded and the minor axis diameter
reported as the representative diameter. In cases where
length is recorded to define the extent of treatment, the
tortuous diseased aorta should be measured in 3-D recon-
structions using the central lumen of the vessel, the vessel
center (including extraluminal components), or a specifi-
cally defined path. Aortic pathology (eg, calcific plaque or
irregularities) or bony landmarks close to the aortic aneu-
rysm may be used as adjunctive landmarks for measure-
ments.
It must be stressed that axial computed tomography
(CT) measurements alone are undesirable for these pur-
poses, and that new studies must use one of the many
available types of 3-D reconstruction. Further details are
included in the section “Classification and measurement of
treatment effects related to TEVAR” and in the Appendix
(online only).
Etiologic classification. It is recommended that re-
ports identify the etiology of the aortic pathology to the
extent possible, in keeping with a classification that includes
anatomy, etiology, and clinicopathologic manifestations
(Table II). With regard to arterial aneurysms, distinction
should be made between degenerative (arteriosclerotic),
anastomotic, infectious, inflammatory (noninfectious),
traumatic, connective tissue disorder, chronic dissection,





Thoracoabdominal (Crawford types I to IV)4
● Type I: begins in the proximal half of the descending tho-
racic aorta (equivalent to “above T6 disc space”), involves
the remainder of the descending thoracic aorta and tran-
scends the diaphragmatic boundary, involving the upper
abdominal aorta without extending below the renal arteries.
● Type II: begins in the proximal half of the descending tho-
racic aorta (“above T6 disc space”), involves most or all of
the descending thoracic aorta and most or all of the abdom-
inal aorta, extends below the renal arteries.
● Type III: involves the distal half (equivalent to “below T6
disc space”) of the descending thoracic aorta and involving
varying segments of the abdominal aorta.
● Type IV: includes most or all of the entire abdominal aorta,
including the renal arteries. These definitions adapted by
Crawford,4 eliminate the Type V category.
Abdominal
● Juxtarenal: aneurysm abuts the renal arteries, but does not
involve the renal arteries (no normal aorta between upper
extent of aneurysm and renal arteries)
● Infrarenal
Iliac involvement (with either thoracoabdominal or abdominal
aortic aneurysm)and congenital aneurysms. Standard naming terminology isTable II. Descriptors of thoracic aortic pathology in




infectious, inflammatory (noninfectious), traumatic,
dissection, connective tissue disorder, and congenital
aneurysms
Clinicopathologic manifestations—Chronic pain, acute severe
pain, emboli, acute rupture, chronic contained rupture,
fistula, compression or erosion of adjacent structures
Traumatic aortic injury







Anatomy—Identify location in ascending, arch, or descending
aorta, or use a standard classification scheme (eg,
Stanford, DeBakey)
—Include as much precision on length, location, and
involvement of aortic branches as possible
Etiology—Spontaneous dissection due to hypertension,
Marfan syndrome, or other connective tissue disorder, or
traumatic dissection (blunt, sharp, iatrogenic)
Time course—Acute or chronic, using 14-day criterion42
Clinicopathologic manifestations—Pain, ischemia, aneurysm,
rupture
Penetrating aortic ulcer
Anatomy—Site, extent, depth of the ulceration, maximum
aortic diameter
Etiology—Degenerative, infectious, iatrogenic
Time course—If acutely manifesting (eg, rupture, emboli)
Clinicopathologic manifestations—Pain, emboli, rupture
Intramural hematoma
Anatomy—Site, extent, thickness of the associated hematoma,
maximum aortic diameter
Etiology—Hypertension, iatrogenic, penetrating ulcer,
aneurysm (see co-existing pathology below)
Time course—If acutely manifesting (eg, rupture)
Clinicopathologic manifestations—Pain, aneurysm, rupture,
compromise of branch arteries
Aortic diverticulum
Anatomy—Standard naming terminology is appropriate (eg,
Kommerell’s diverticulum)
—Anatomic description of location appropriate to make the
pathology and location clear
—Dtudies demonstrating compressive effect (computed
tomography, magnetic resonance, esophageal area,
endoscopy findings)
Associated abnormalities—Right-sided aortic arch, aberrant
subclavian artery, etc
Clinicopathologic manifestations—Dysphagia, emboli, pain,
etc, including severity
Coexisting pathology
—All pertinent should be listed
—The primary pathologic entity should be designated
accordingly
—Standard classifications of type, etiology, time course and
clinicopathologic manifestations
—All types of pathology should be accompanied by
hemodynamic status at presentation/repair: stable,
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ticulum) but should be accompanied by a brief anatomic
description to make the pathology clear, as well as associ-
ated abnormalities such as right-sided aortic arch and aber-
rant anatomy of other arch vessels. When multiple types of
pathology coexist and are pertinent to repair, such as dis-
section with a corresponding aneurysm, the primary patho-
logic entity should be designated in addition to describing
other pertinent pathology.
Clinical classification. Aneurysms and other patho-
logic entities should be categorized by clinical presentation
as asymptomatic or symptomatic. Pertinent symptoms, time
course, and severity should be documented, including those
related to compression or erosion into neighboring struc-
tures, thrombosis, embolization, or end-organ ischemia.
Rupture should distinguish between a free or contained
rupture and fistulization into adjacent structures. In this
regard, hemodynamic status of the patient should be re-
ported, including blood pressure and response to the initial
resuscitation (stable, unstable, cardiac arrest). Reports on
intramural hematomas or dissections should include the
elapsed time between onset and therapy, with a clear defi-
nition of acute and chronic. Patients presenting with symp-
toms occurring 2 weeks of a clearly defined new patho-
logic entity may be considered acute, whereas those treated
thereafter are considered chronic. Although this time frame
is arbitrary for intramural hematoma, it is to be consistent
with the definition of acute for dissections, based on au-
topsy studies showing that 74% of patients who die of aortic
dissections do so within the first 14 days.10 Dysphagia or
other compressive effects due to the aortic pathology
should be described by time course and severity.
CATEGORIZATION OF OPERATIONS AND
PROCEDURES
Operative and procedural details, including all the ad-
ditional procedures necessary to maintain a clinically dura-
ble result, will determine the magnitude, complexity, and
expense of TEVAR. Therefore, careful reporting will assist
in efforts designed to enhance treatment efficacy with revi-
sion of patient selection criteria, improvement of intraop-
erative adjuncts, or refinement of device design. In all cases,
identification of procedural goals, maneuvers, device com-
ponents, and configurations is important.
Categorization of endograft configurations and
components. Precise description of the configuration,
modularity, fabric, support, and fixation structures of the
endograft system should be provided, if not detailed in a
prior report. There must also be an accounting of all
adjunctive components, devices, and maneuvers. Recom-
mendations regarding uniform reporting of device config-
uration and components are outlined in Table III and are
detailed in the online Appendix.
Configuration: Branch treatments, branched and
fenestrated endografts. The newest and most complex
issue in reporting TEVAR stent graft configuration is for
branch vessel treatment. The aortic stent graft configura-
tion may be modified in a number of ways to treat aorticbranch vessels. The term scallop refers to a portion of aortic
graft material removed to accommodate an aortic branch at
the proximal or distal end of the aortic repair, thus allowing
some fabric to extend further proximally or distally than a
simple cylindrical configuration would allow. The term
fenestration or fenestrated may be used to indicate the
presence of openings purposely created within the en-
dograft to allow perfusion of visceral or brachiocephalic
arteries in the region otherwise covered by the aortic en-
dograft. If stents are placed within fenestrations, the fre-
quency should be noted and designated by a term such as
Table III. Categorization of endograft configurations
and components
Configuration
● Location: Proximal (zones 0-7, see text), distal (relative to
visceral aortic branches, zones 4-11, see text)
● Length of coverage: Length (cm) or proportion of descend-
ing thoracic aorta covered
● Modularity: Single or multiple components
● Diameter: Straight or tapered
● Branch vessel treatments to an aortic stent graft:
Scallop, fenestration, stented fenestration, fenestrated branch,
side-arm branch (see text for definitions)
Number of vessels treated (intent to treat)
Type and number of components (eg, balloon-expandable or
self-expanding stent grafts)
● Retrograde, antegrade branches
● Branch vessel adjuncts (eg, chimney or snorkel technique,
debranching—see text)
Endograft fabric (eg, polytetrafluoroethylene, polyester,
combination, fabric “generation”)
Support system
● Full or partial support
● Balloon-expandable or self-expanding
● Stent framework luminal or abluminal in relation to the
fabric
● Supporting framework fixed to the graft with stitches or
otherwise bonded, attached
● Geometric configuration
● Material composition (eg, nitinol, stainless steel, Elgiloy);
describe nonstandard alloys
Fixation components and techniques
● Integral part of the support skeleton or a separate or unique
element of the endograft system
● Configuration (hooks, barbs, screws, pins, scales, or other
means)
● Balloon or self-expanding
● Intended placement of a fixation system (eg, proximal or
distal to branch vessel origins)
● Endograft extensions and intraluminal stents
● Adjunctive devices to assure proper fixation, sealing,
patency, and positioning of the endograft (eg, adjunctive
intraluminal balloon-expandable or self-expanding stents,
unplanned stent raft components of another manufacturer,
extensions that would not be typical of the device, or
unplanned extensions)
Graft size relative to the native aorta
● Percentage of graft oversizing relative to the host artery
diameter at the intended fixation sites
● Oversizing relative to lumen or outer vessel wall
● Reported as an absolute number or preferably as a range
and average percent of over-sizingstented fenestrations. If a stent graft is placed within a
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would still be stented fenestration.
The prefix branched is used to indicate the presence of
stent graft side arms intended to connect the primary aortic
endograft to visceral or brachiocephalic arteries in the re-
gion otherwise covered by the aortic endograft. The impli-
cation is that a stent graft branch is required for sealing
across a gap between the primary aortic endograft and the
target visceral or arch vessel (ie, a fenestration or stented
fenestration would allow flow or pressurization of the an-
eurysm sac). A fenestrated branch seals into a fenestration
that has been reinforced to allow sealing, and a side-arm
branch implies a side arm has been sewn onto the aortic
stent graft component to allow sealing. The type of branch
should be reported, as well as whether the branch is ori-
ented antegrade or retrograde. For branches and fenestra-
tions, the vessels intended to receive scallops, fenestrations,
stented fenestrations, or stent grafts should be described, as
well as the total number of stent grafts or stents required.
Other treatments for aortic branches may affect the
primary aortic stent graft(s). As such, they must be re-
ported, and the definition is included with graft configura-
tion even though the treatment may not technically modify
the primary aortic endograft configuration. Branch treat-
ments include debranching of the visceral or arch vessels,
which is defined as a surgical bypass performed to originate
perfusion of the aortic branch artery from a location that
will not be covered by the intended aortic stent graft (eg,
iliac-renal bypass, carotid-subclavian bypass). The other
commonly described branch treatment is the placement of
a stent or stent graft in an aortic branch artery that is
covered or partially covered by the aortic stent graft, typi-
cally referred to as the chimney or snorkel technique. Re-
ports of these treatments should include the number and
type of stents, stent grafts, or grafts used and whether the
treatment was planned or unplanned.
Zones of attachment. The location of attachment
and length of coverage relates to the risk and complexity of
the procedure as well as component selection and stresses
on the devices. A system is already in place to describe the
proximal zones of attachment, originally proposed to de-
scribe the ascending aorta, arch, and proximal descending
aorta (zones 0-4).11,12 Reporting the proximal attachment
zone is particularly important when reporting neurologic
outcomes, because cerebrovascular outcomes appear to be
related to the proximal attachment site zone.11,13 Both the
proximal and distal attachment zone likely affect patient
risk, device selection, complexity of the procedure, and
stresses on devices,14 so an extended “zone” system is
described here that allows for a complete description of
both proximal and distal attachment site by zone. See the
Fig in addition to the following:
● Proximal attachment zone: Proximal endograft attach-
ment site, defining the proximal edge of covered en-
dograft. Zone 0  the proximal edge of the covered
endograft is proximal to the innominate artery origin;
1  distal to the innominate but proximal to the leftcommon carotid artery (LCCA) origin; 2  distal to
the LCCA but proximal to the subclavian artery; 3 
2 cm of the left subclavian artery without covering it;
4 proximal extent of the endograft is2 cm distal to
the left subclavian artery and ends within the proximal
half of the descending thoracic aorta (T6 approximat-
ing the midpoint of the descending thoracic aorta);
5  starts in the distal half of the descending thoracic
aorta but proximal to the celiac artery; 6 celiac origin
to the top of the superior mesenteric artery (SMA);
and 7 SMAorigin, suprarenal aorta. For devices with
bare stents, it is useful to differentiate the covered and
noncovered end point.
● Distal attachment zone: Distal endograft attachment
site, defining the distal edge of covered endograft.
Zone 4 distal extent of the endograft is2 cm distal
to the left subclavian artery and within the proximal
half of the descending thoracic aorta (T6 approximat-
ing the midpoint of the descending thoracic aorta);
5  ends in the distal half of the descending thoracic
aorta but proximal to the celiac artery; 6  covers the
Fig. Zones of attachment. See text in the main document and the
online Appendix for more details.celiac, ends proximal to the SMA; 7 covers the SMA,
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renal artery; 9  infrarenal; 10  common iliac; 11 
external iliac. For iliac arteries, the zone can be re-
ported separately or by the most distal site (eg, if one
side ends in the common iliac artery and the other ends
in the external iliac artery, use zone 11). For devices
with bare stents, it may be useful to differentiate the
covered and noncovered end point. For extensive re-
pairs, the status of both internal iliac arteries should be
reported (patent, chronically occluded, or coiled/cov-
ered by the repair).
Alternatively, the distal attachment location may be
reported relative to the anatomic segment, namely de-
scending thoracic aorta (eg, proximal third, middle third,
or distal third), the visceral aortic segment (describing the
branches that are covered), the infrarenal aorta, the com-
mon iliac, or the external iliac arteries. For extensive repairs,
the status of the internal iliac arteries should be reported
(patent, chronically occluded, or coiled/covered by the
repair).
Other aspects. Other aspects of stent graft configura-
tion, including location, length, modularity, fabric, support
system, fixation, as outlined in Table III, are described in
detail in the online Appendix.
Description of the principle or primary procedure.
A principal procedure is one that the surgeon believes
contributes most to treatment of the aortic pathology and
therefore involves placement of the aortic endograft com-
ponents in reports of TEVAR. The primary pathologic
entity designated for treatment must be described as de-
tailed in “Classification criteria for thoracic aortic pathol-
ogy” and Table II. Formost reports, the procedure will also
largely be described by the categorization of the device
configuration (eg, location, branch treatments, etc) as re-
ported in Table III and the adjunctive procedures as de-
scribed below and in Table IV.
Adjunctive maneuvers and concomitant or staged
procedures: Preoperative, intraoperative, and posto-
perative. A principal procedure is one that the surgeon
believes to contribute most to treatment of the aortic
pathology, and therefore involves placement of the aortic
endograft components in reports of TEVAR. An adjunctive
procedure is any other procedure that is designed to aug-
ment the effects of the principal procedure, such as de-
branching an aortic segment by a bypass (eg, carotid-
carotid artery bypass, iliac-celiac artery bypass), stenting a
branch artery (eg, for a pre-existing stenosis), or use of a
stent, conduit, or bypass as an aide to device delivery (eg,
treating an iliac artery stenosis with stenting, placement of
an internal iliac conduit, or a bypass graft used as a conduit
for the delivery system). Adjunctive procedure types are
outlined in Table IV. Such procedures may occur in the
preoperative, intraoperative, or postoperative periods and
should be designated in like manner.
Primary procedures refer to all interventions performed
during the initial aortic endovascular repair and serve as the
reference point for these designations. Adjunctive proce-dures can be “preoperative” if the procedure is staged (eg,
debranching before aortic stent grafting). “Intraoperative”
adjuncts may also be designated as concomitant procedures,
and should be further described as planned or unplanned
when appropriate. Adjunctive procedures would rarely be
designated as “postoperative,” because postoperative ad-
juncts would typically be unplanned secondary interven-
tions designed to treat a problem with the primary repair.
One example of a postoperative adjunctive procedure
would be a carotid-subclavian bypass that was planned for
the primary procedure but was staged in a delayed fashion
due to patient instability at the time of the primary proce-
dure. Thus, secondary procedures include essentially all op-
erations or endovascular interventions performed at a later
date.
Conversion to open surgical repair. Conversion from
endovascular to open repair may be required at the original
operation (primary conversion) or on a subsequent occasion
(secondary conversion). Secondary conversion also should
be classified as urgent or elective. For example, secondary
conversion for persistent endoleak in an asymptomatic an-
eurysm is an elective procedure, and conversion precipi-
tated by aneurysm rupture is an urgent or emergent inter-
vention. Details of conversion should be reported,
including indication, site of aortic control, and other rele-
Table IV. Categorization of adjunctive procedures
Hemodynamic adjuncts
Lowering systemic blood pressure
Altering cardiac inflow (eg, atrial balloon)
















Typically part of the primary procedure for branched
endografts
Aortic attachment adjuncts
Bare stents, stent graft extensions, external wraps
Aortic sac adjuncts
Coils, glue, or other pharmacologic treatment
Monitoring or therapeutic adjuncts
Pressure monitoring devices
Cerebrospinal fluid drainage
Somatosensory or motor-evoked potentials
Adjuncts for device delivery
Stent
Internal conduit (stent graft)
Temporary surgical conduit
Bypass (for delivery conduit)vant operative information. Open surgical aortic arch repair
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be caused by stent graft placement would be categorized as
a complication with secondary open intervention. Al-
though the latter would not be classified as an open surgical
conversion, it would be of equivalent significance and
should be reported clearly.
CLASSIFICATION AND MEASUREMENT OF
TREATMENT EFFECTS RELATED TO TEVAR
The primary goal of TEVAR for any pathologic entity is
to prevent death secondary to the pathology or related
interventions. Death or rupture may occur in quite a de-
layed fashion, even in ineffective repairs, so surrogates of
device efficacy that can be measured in the near term are
desirable. The aneurysm sac in EVAR is left intact, and this
feature is important in outcome assessment. Specifically,
clinical correlation suggests that aneurysm expansion after
EVAR is an indicator of incomplete aneurysm exclusion,
continued risk of aneurysm rupture, and a presumed treat-
ment failure.2 Because variations in size occur in three
dimensions, both sac diameter and volume are relevant
parameters for defining changes in aneurysm size. It is
noteworthy that relatively small diameter shifts of 1 to 2
mm, whichmay otherwise be difficult to accurately measure
with conventional imaging techniques, may be correlated
with a significant change in aneurysm volume.2,15-18 Other
pathologies can be evaluated, at least partially, using similar
techniques. For intramural hematoma, measurement of the
longitudinal extent and thickness are important and may be
captured and/or measured in similar fashion to aneurysm
diameter and volume. Similarly, traumatic aortic injury and
dissection are often associated with aneurysm, and changes
in the aneurysm size may be a secondary outcome measure
as a surrogate of treatment effect in these cases.
Measurement of device migration, attachment site ap-
position length, device diameter, modular component
overlap, and angulation are analogous to surrogate end
points involving the aneurysm sac and may serve as indica-
tors of device stability in all types of TEVAR. Measures of
branch vessel change are critical in branched endograft
repair of thoracoabdominal or thoracic aneurysm, but may
be important in traumatic aortic injury, dissection, or even
relatively straightforward TEVAR for aneurysm.
Thus, reports pertaining to the implementation of
TEVAR may include measures of diameter, length, vol-
ume, endoleak, attachment site dimensions, migration,
tortuosity, and branch vessel morphology, as outlined in
Table V. Recommendations regarding the methodology
for calculating key measurements are included in the online
Appendix. Some of these parameters are more pertinent for
clinical trials of new devices or research studies, but at a
minimum, reports of TEVAR must include a measure of
aortic size (covered below), exclusion of the pathologic
entity of endoleak (Table VI and online Appendix), device
stability, includingmigration (online Appendix), and device
integrity (covered in the next section).
Changes in aneurysm dimension. Measurable changes
in aortic and aneurysm dimensions have been repor-ted immediately after endograft deployment. Therefore,
changes in size should be referenced to measurements
obtained from the first set of postoperative images. At each
time point, aneurysm size should be expressed as maximum
diameter measured orthogonal (perpendicular) to the lu-
men centerline or vessel centerline. If available, aneurysm
size should also be reported for sac volume, which appears
to be more sensitive for detecting aneurysm size cha-
nge.2,15-18 Volume can be measured by total volume or by
measuring the device and sac volumes as separate compo-
nents (Table V and online Appendix). Deviations from this
method of measurement should be detailed in any report.
Comparisons between time points should use a poten-
tial measurement error of 5mmdiameter or 10% change for
volume measurements, unless data supporting alternative
intraobserver or interobserver variability is reported based
on percent change or absolute value in mL. Modality,
method, and definitions should be clearly described, and
Table V. Key measurements for reports pertaining to
thoracic endovascular aneurysm repair
1. Diameter: Measured perpendicular to 3-D centerline flow or
minor axis of axial computed tomography
2. Volume: Documented to be more sensitive to aneurysm size
change than diameter Preferably measured external to the
lumen of the endograft, as a percentage of baseline
measurement or in cubic centimeters
3. Length of the aneurysm and/or dissection: 3-D centerline
measurement from vessel centerline or lumen centerline
a. Distance between two reproducible anatomic aortic
landmarks on the imaging study
b. Anatomic non-aortic landmarks found on adjacent
structures
c. Requires a measure of stability of the total aortic length
(including untreated segment)
d. Can be expressed in simple absolute measurements (ie, mm)
and as a percentage of total length between two defined
landmarks (eg, subclavian and celiac artery branches)
4. Endoleak: See Table VI and online Appendix.
5. Aortic attachment site diameter change: Perpendicular to
vessel/lumen centerline or minor axis of axial computed
tomography
6. Aortic attachment site apposition length (seal zone): 3-D
centerline measurement
7. Device migration: 3-D centerline measurement
a. Distance between two reproducible anatomic aortic
landmarks on the imaging study
b. Anatomic nonaortic landmarks found on adjacent structures
c. Requires a measure of stability of the total aortic length
(including untreated segment)
8. Intercomponent relationships (eg, changes in overlap,
attachment)
9. Aortic or device tortuosity, angulation, or radius of curvature
10. Adjacent aortic branch vessel change
a. Diameter: Perpendicular to vessel/lumen centerline or
minor axis of axial computed tomography
b. Angle: 3-D measurement strongly preferred
c. Stenosis or occlusion
The above measurements should be reported in mm or to the tenth of a cm
(eg, 6.2 cm) unless otherwise specified. Recommendations regarding the
methodology for calculating key measurements are included in the online
Appendix.comparisons should only be made between identical meth-
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further discussion of these measurements and other mea-
surements, including endoleak and migration.
Imaging modalities and follow-up sequence for
measuring changes in aneurysm morphology and cate-
gorizing outcomes. Imaging studies are currently recom-
mended at discharge or at least 1 month of the procedure,
and periodically thereafter. At a minimum, annual follow-up
studies were conducted by all of the prospective U.S.
clinical trials. Follow-up studies typically include high-
resolution, contrast-enhanced spiral CT studies of the chest
and abdomen. The study should cover the device from start
point to end point, and initially the delivery system access
site should ideally be imaged by CT or duplex ultrasound
imaging. Follow-up studies also typically include plain ra-
diographic images of the appropriate anatomic region to
assess thoracic device fracture. Although noncontrast CT
studies can be used to assess aneurysm size, the presence or
absence of an endoleak can only be determined with a
contrast-enhanced imaging study. Magnetic resonance im-
aging (MRI) may be substituted for CT scans if the signal
void created by the implanted device is minimal (2 mm).
Recommendations for follow-up and MRI compatibility
should be found in the instructions for use for any device.
Methodology for documenting the integrity of an
endoprosthesis. The integrity of the endovascular device
may be compromised at the time of deployment (early
device failure) or later after graft implantation (late device
Table VI. Endoleak definitions
Type I:
a. Leak at the proximal graft attachment site
b. Leak at the distal graft attachment site
c. Leak around a fenestration, branch end point, or branch
occluding plug (eg, plug occluding a subclavian artery or
iliac artery to prevent flow into an aneurysm sac2)
Type II: Retrograde flow from branch arteries arising from the
excluded segment
Type III:
a. Modular disconnect or apposition failure (including branch
junctions)
b. Fabric tear
Type IV: Flow through porous fabric (generally resolves within a
short time period, typically less than 24 hours)
Type V: No detected endoleak, but aneurysm expansion (thus
presumed failure to detect the endoleak or presumed
pressure transmission through thrombus without blood
flow)
Note: Endoleaks must be stratified by
1. Time of endoleak occurrence (primary, secondary,
recurrent)
2. Site of endoleak origin
3. The proportion of patients with an endoleak and confirmed
aneurysm expansion
4. The proportion of patients without detectable endoleak
with demonstrable aneurysm expansion (ie, possible
endotension)
The number of patients available for analysis must be specified at each time
point. Full definitions of endoleak types and reporting methods are included
in the online Appendix.failure). If disruption of a component of the prosthesis isobserved at deployment, the role of delivery system failure
and operator error should be noted, including inappropri-
ate patient selection or technical misjudgment. Failure of
the delivery system and related adjuncts should be reported
separately as access or delivery system issues, and not
grouped with failures of the implanted endoprosthesis.
Late deformation of endografts should be defined by
whether there is associated device obstruction or compo-
nent module disconnection. A progressive change in angu-
lation over time remains an area of investigation, and if
reported, it should include the initial angulation and the
change in angulation over time based on a clear definition.
The site of angulation should be specified by proximity to
anatomic landmarks, the distance from graft attachment,
and the length over which the angulation is measured.
Angulation is best measured on 3-D reconstructions of the
endograft, because plain radiographs tend to underestimate
angulation or cause ambiguities in measurement.
Noninvasive assessment of the integrity of metallic graft
components is typically determined by plain radiographs
obtained in the anteroposterior, lateral, and oblique posi-
tions. High-resolution spiral CT scan imaging can be used
as a supplement to plain radiographs or may substitute for
plain radiographs if 3-D reconstructed views allow for
proper assessment of the metallic components of the device
(if resolution is adequate and demonstrated by validation vs
conventional radiography in the same report or a prior
report). All imaging methods have limited ability to detect
fabric failure, and the methodology for detection should be
described (eg, delayed contrast CT angiography or MR
angiography, conventional angiography, angiography with
outflow occlusion to create a standing column of contrast
within the implant, or explant). The prevalence of a fabric
or metallic structural failure in a carefully studied, uns-
elected, and numerically significant subset of implanted
devices can serve as an estimate of device failure.
Grading system for reporting device failures. The
clinical significance of reported device failures should be
stratified as:
0—not associated with an adverse clinical event or necessi-
tating increased surveillance or intervention;
1—necessitating increased surveillance but without clinical
event;
2—necessitating intervention to control or manage;
3—resulting in conversion, rupture, major complication, or
death.
Reports of late device failure should also include poten-
tially relevant clinical, anatomic, and hemodynamic param-
eters, such as implant duration, associated changes in aortic
or implant morphology, and blood pressure.
OUTCOME CRITERIA AND DEFINITIONS
The motivation for treatment of thoracic aortic pathol-
ogy is to minimize the mortality and morbidity associated
with the pathology. The method of accomplishing this goal
varies slightly, depending on the pathologic entity, but is
primarily designed to reduce or eliminate the risk of aortic
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 4 Fillinger et al 1029rupture, end-organ ischemia secondary to embolization or
malperfusion, new or progressive dissection, paraplegia,
and death. The indications for treatment and the resulting
outcomes must be reported, because they are critical for
comparison of studies and for meta-analysis.
Primary and secondary outcome criteria. The goal
of minimizing patient morbidity andmortality is, of course,
related to the interventions as well as to the pathologic
entity. Therefore, by definition, the primary outcome crite-
ria for TEVAR includes the prevention of rupture and
death related to the primary pathologic entity or to a
procedure designed to treat it (Table VII).
It is initially difficult to determine whether placement
of an endovascular graft has prevented or reduced the risk
of rupture or death, however, because these outcomes may
only occur after substantial time has passed. Thus, surro-
gate markers that suggest a continuing or increasing risk
from the original pathology may play a critical role in the
overall assessment of the effectiveness of endovascular
treatment strategies. Surrogate markers and markers of
patient morbidity should be designated as secondary out-
come criteria and may include the conditions listed in Table
VII. Conversion to open repair of the pathology represents
a special type of failure of the endovascular technique and
should be reported clearly and uniquely from other types of
secondary intervention. Significant value exists in reporting
an accepted and unifying measure of clinical success that
Table VII. Primary and secondary outcome criteria for
thoracic endovascular aneurysm repair
Primary outcome criteria
1. Prevention of rupture of aortic aneurysm or other aortic
pathology
2. Prevention of death from aneurysm rupture or other aortic
pathology (including end-organ ischemia)
3. Prevention of death associated with primary or secondary
treatment of the original aortic pathology, including
operative or endovascular intervention for rupture,
dissection, or end-organ ischemia (eg, stroke, transient
ischemic attack, mesenteric or renal infarction or ischemia,
upper or lower extremity ischemia)
Secondary outcome criteria (surrogate markers and markers of
patient morbidity)
1. New, expanding, or progressing: aneurysm, dissection,
ulceration, or hematoma
2. Device migration
3. Device degradation (eg, stent fracture, fabric erosion)
4. Endoleak presence (for aneurysm)
5. Endoleak requiring intervention
6. Hospital admission for medical treatment of the original
pathology or its sequelae
7. Neurologic events (stroke, transient ischemic attack,
paraplegia, paraparesis)
8. Embolic phenomena
9. Ongoing ischemia (eg, mesenteric ischemia, renal failure,
claudication)
10. Complications of adjunct procedures performed to
facilitate the implantation of the endograft (eg, occlusion
of debranching bypass graft)
11. Conversion to open repaircombines the most significant primary and secondary out-come criteria, which reflect the goals of this treatment
method (see also “Reporting deaths and complications”
below).
Definition of success. Defining the success of TEVAR
remains dependent on a consideration of both clinical and
radiographic criteria that exist within the context of histor-
ical standards established by open surgical repair as well as
by EVAR. For direct analogy to open repair, a similar result
can only be accomplished with an endograft if complete
exclusion of the pathology from the circulatory system is
achieved. Some investigators, however, have suggested that
the presence of a persistent type II endoleak after EVAR
may or may not be a predictor of late adverse outcomes,
including aneurysm expansion and rupture.19-21 Less data
exist regarding type II endoleak after TEVAR than after
EVAR. In the absence of definitive data, the relative pre-
dictive value for endoleak and other surrogate outcome
markers remain incompletely defined and should continue
to be reported with all reports pertaining to TEVAR.
Definition of technical success. Technical success
relates to immediate periprocedural events that occur from
the initiation of the procedure and extend through the first
24 hours postoperatively. Primary technical success is de-
fined on an intent-to-treat basis that begins with the im-
plantation procedure and requires the successful introduc-
tion and deployment of the device in the absence of surgical
conversion to open repair, death 24 hours, type I or III
endoleaks as evidenced by procedural angiography, or graft
obstruction. A technical success thus implies the following
qualifying details are all met:
1. successful access to the arterial system using a remote
site (ie, the femoral, external iliac, common iliac, ab-
dominal aorta, or brachiocephalic arteries with or with-
out use of a temporary or permanent prosthetic conduit
to access these arteries);
2. successful deployment of the endoluminal graft at the
intended location;
3. absence of a type I or III endoleak (angiographically
detected);
4. patent endoluminal graft without severe obstruction (ie,
the mean pressure gradient should be 10 mm Hg by
intraoperative measurements).
Secondary technical end points should be reported,
such as procedure time, blood loss, blood transfusion,
fluoroscopy time, contrast load, range and average number
of days in an intensive care unit, and hospital length of stay
(preferablymean,median, and range). These parameters do
not enter into the consideration of the primary technical
success rates.
Definitions of clinical success. Primary clinical suc-
cess should be reported on an intent-to-treat basis and
initially requires successful deployment of the endovascular
device at the intended location. Ongoing primary clinical
success is further defined as freedom from the need for an
unplanned additional (secondary) surgical or endovascular
procedure targeted at the pathology that was initially
treated or targeted at new pathology caused by the index
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the following: death as a result of treatment or as a result of
the original pathology that was treated; type I or III en-
doleak, infection or aortic thrombosis; aneurysm expansion
(diameter5mm, volume10% or greater than two times
interobserver variability) or rupture; conversion to open
repair; or failure to arrest the original pathologic process
(eg, embolization from penetrating ulcer) or causing a new
thoracic aortic pathology as a result of the intervention (eg,
pseudoaneurysm, dissection, intramural hematoma).
Assisted primary clinical success is defined as clinical
success achieved initially and continuously maintained, but
only with the use of an additional procedure deemed nec-
essary to prevent failure of the initial implant(s).
Secondary clinical success is defined as clinical success
obtained initially but temporarily interrupted by a failure
that is corrected with the use of an additional, secondary
surgical procedure; for example, a type I endoleak develops
in an initially excluded aneurysm due to endograft migra-
tion at 2 years and is corrected by placement of a new, more
proximal endograft. Conversely, clinical failure includes
death as a result of treatment or as a result of the original
pathology that was treated or a pathology caused by the
initial procedure (eg, aneurysm rupture, or dissection ex-
tending to cause mesenteric ischemia and resulting in
death), type I or III endoleak, graft migration, infection, or
thrombosis, aneurysm expansion (as defined elsewhere in
this document; aneurysm rupture), conversion to open
repair, failure to arrest the original pathologic process, or
appearance of a new thoracic aortic pathology as a result of
intervention.
Endograft integrity problems should be reported sepa-
rately and include graft dilatation of 20% by diameter
relative to nominal size at implant, wire fracture, graft
migration, or other failure of device integrity. Clinical
success can be claimed for those cases with a type II
endoleak only in the absence of aneurysm expansion.
Definitions of success relative to length of follow-up.
The presentation of clinically meaningful success rates man-
dates that the data are statistically valid for the time period
in question. Specifically, the standard deviation of life-table
or Kaplan-Meier estimates should not exceed 10%, as noted in
other Society for Vascular Surgery reporting standards. The
following temporal characterization of clinical success is
consistent with the EVAR standards. Initial or 30-day
clinical success is defined to encompass data 30 days after
the procedure. Short-term clinical success includes outcome
measures reported from 30 days to 6 months. Midterm
clinical success refers to all outcome measures that are
statistically significant 5 years after endograft implanta-
tion. Long-term clinical success includes all outcome mea-
sures that are statistically significant 5 years.
Aortic rupture or aneurysm rupture should be reported
as a procedure-related rupture (eg, perforation of the aorta
or aneurysm during the course of the implantation proce-
dure) or as a late rupture that occurs in delayed fashion
(24 hours) after completion of the procedure.Reporting deaths and complications. Standardized
reporting of deaths and complications is necessary to estab-
lish TEVAR as a safe and effective therapy for aortic pathol-
ogy and to compare TEVAR between different devices or
with conventional surgery for patients at low and high risk.
Deaths and complications should be reported on an intent-
to-treat basis. Intent-to-treat should be considered initiated
by any maneuver directed at treating the aneurysm with an
endovascular approach or the first adjunctive procedure
(eg, debranching) in a staged approach.
Deaths. All deaths that occur 30 days of the opera-
tive procedure should be categorized as TEVAR-related
deaths (ie, aneurysm-related deaths in the case of aneurysm
repair), and classified as either procedure-related or device-
related. Deaths that occur 30 days should be considered
late deaths, with the additional categorization of in-hospital
late death for those patients who died 30 days after the
procedure but never left the hospital. The cause of late
death and its relationship to the implanted device or pro-
cedure should be noted. TEVAR-related deaths should be
reported explicitly and are defined as all deaths due to the
treated pathology, including aneurysm rupture, a primary
or secondary procedure, surgical conversion, or complica-
tions of TEVAR leading to new aortic pathology (eg,
retrograde dissection leading to fatal cardiac tamponade).
The cause of death should be classified as verified if
determined on the basis of autopsy findings, direct surgical
observation that defines the status of the aneurysm, or
definitive imaging studies of the endograft obtained during
the patient’s terminal illness. When this level of information
is unavailable, the cause and its relationship to the proce-
dure and device should be classified as probable if the clinical
picture is consistent and documented with reliable obser-
vations during the terminal illness. When these criteria
cannot be met, the cause of death should be considered
indeterminate.
Complications and complications grading system.
Complications should be assigned a severity score so that
degrees of morbidity can be assessed and compared. A
specific complication and morbidity grading system already
exists in the EVAR standards, and can be used for TEVAR.2
See also “Other key aspects” below.
Grading system for spinal cord ischemia. One rec-
ommended modification to the existing EVAR standards is
for the spinal cord ischemia grading system:
0  none;
1  resolved with minimal sensory deficit, able to walk
independently;
2  minor motor deficit, able to walk with assistance or
independently (implies the ability tomove against grav-
ity);
3a  nonambulatory (wheelchair bound), able to move
against gravity;
3b nonambulatory (wheelchair bound), able tomove the
extremity laterally but not against gravity; and
3c  nonambulatory (wheelchair bound), minimal or no
movement.
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tems,22 while maintaining the standard, clinically useful
“mild, moderate, or severe” grading system (see next sec-
tion). Complications such as paraplegia or paraparesis are
most appropriately expressed in status at a particular time
point (eg, 1month postoperatively, 1 year postoperatively),
and progression from one level of severity to another can be
noted.
Grading system for complications without an exist-
ing grading system. The following scoring system has
been modified from Rutherford et al23 for uncommon
complications without a specific grading system and is
consistent with the EVAR reporting standards2,3:
● Mild indicates the complication occurred but resolved
spontaneously or with nominal intervention, did not
prolong hospital stay, and did not cause permanent
impairment.
● Moderate indicates the need for significant interven-
tion, prolongation of hospitalization 24 hours, and
at most, minor permanent disability that does not
preclude normal daily activity.
● Severe indicates the need for major surgical or medical
intervention, may be associated with prolonged con-
valescence, is usually accompanied by prolonged or
permanent disability, and may result in death.2,24
Other key aspects. All complications should be clas-
sified as procedure-related or device-related, and anatomic
site and presumed etiology should be reported where ap-
propriate. All complications graded as moderate (2) or
severe (3) are considered major complications, and those
graded as mild (1) can be considered minor complications.
Longitudinal reporting of clinical outcome mea-
sures. The following parameters are recommended for
inclusion in any comprehensive report of TEVAR: survival,
rupture-free survival, aneurysm-related death, freedom from
aneurysm expansion, freedom from type I and III endoleaks,
prevalence of type II endoleak, prevalence of secondary en-
doleak, endograft patency, and technical and clinical success
rates. Aneurysm rupture may be uncommon for other types
of pathology but should still be reported (rupture can occur
with traumatic injury, dissection, penetrating ulcer, intra-
mural hematoma, and diverticula). All pathologic entities
should also have survival free from death or major morbid-
ity related to the pathology (eg, freedom from emboli,
neurologic events, end-organ ischemia).
Life tables or Kaplan-Meier curves should be calculated
when reporting survival, rupture-free survival, maintenance
of clinical success, freedom from death related to the aortic
pathology (aneurysm, dissection, etc), as well as for free-
dom from surrogate end points such as aneurysm expan-
sion, type I or III endoleaks, and new or progressing
dissection, embolization, among others, as defined previ-
ously. Because all thoracic repairs are adjacent to or may
involve major branch vessels, a separate analysis should be
considered that reports parameters relevant to long-term
branch artery patency or occlusion, such as stroke, arm
symptoms, mesenteric ischemia, unintended weight loss,segmental renal infarcts, glomerular filtration rates, hyper-
tension, dialysis, claudication, and amputation. Reports of
endograft patency should use life-table or Kaplan-Meier
format and standard definitions of primary, assisted pri-
mary, or secondary patency, depending on the use of
additional endovascular or surgical procedures.
Longitudinal reporting of morphologic changes.
Although the life-table format is ideal for reporting binary
outcomes (eg, freedom from mortality, freedom from an-
eurysm expansion), a format that allows multiple outcomes
may be best to present the details of morphologic changes.
In the case of aneurysm sac morphology, for example, a
complete report should include the percentage of aneu-
rysms that have significant sac shrinkage as well as sac
expansion or lack of significant change.Nonbinary outcomes
in aneurysm or lumen dimension should be reported as the
number of available individuals at each time period; for
example:
Of 100 implanted devices, 80 had appropriate imaging
for evaluation at 1 year. At 1 year, there were 20 aneu-
rysms with significant reduction in sac diameter (5
mm), 10 with significant enlargement (5 mm), and 50
with no significant change in aortic aneurysm diameter or
volume.
Data of this type can be displayed as a stacked bar graph,
stacking the multiple outcome types (in this case, expan-
sion, shrinkage, no change) for each bar to clearly display
the number of aneurysms with the outcome at each desig-
nated time point. The stacked bar format thus displays the
total number of cases at each time point as well and permits
data display for multiple years, without requiring a large
amount of explanatory text.
For research reports in particular, other methods to
describe morphologic changes over time may be useful (eg,
to report neck angulation or aortoiliac tortuosity, where
binary or tertiary outcome standards have been suggested
but not defined).2,3 In these cases, the mean and standard
deviation, or median, range, and quartile values may be
reported to describe morphologic characteristics at specific
time points. In each case, however, the number of cases
being evaluated at each time point must be clearly stated.
For reports of this type, attempts to categorize anatomic
variables into nominal groupings (eg, mild, moderate, se-
vere) are encouraged if the goal is to define a variable that
may predict outcome.3
Comparing the clinical success of endovascular with
open surgical repair. Investigations that compare open
surgical repair with endovascular repair should report pri-
mary outcome criteria for both treatment groups, as previ-
ously defined. The use of related, although distinct, defini-
tions of clinical success are necessary for patients treated
with open surgery. Primary technical success for open surgi-
cal repair should be reported on an intent-to-treat basis
(beginning with the onset of the operative procedure) and
should require replacement or bypass of the pathologic
segment with a prosthetic graft in the absence of death,
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the initial 24-hour postoperative period.
The definition of clinical success for open surgical repair
includes the absence of death as the result of the procedure,
graft infection or thrombosis, failure of device integrity,
including graft dilatation 20% compared with the nomi-
nal diameter, and para-anastomotic aneurysm formation.
Should open repair consist of aneurysm exclusion and
bypass grafting, rupture or expansion of the treated aneu-
rysm (diameter 5 mm, volume 10% or twice interob-
server variability) would classify a case as a clinical failure.
Definitions of initial (30-day), short-term, midterm, and
long-term clinical success and of primary, assisted primary,
and secondary clinical success otherwise remain as de-
scribed elsewhere in this document, as do recommenda-
tions for longitudinal reporting of clinical data.
Other significant outcome variables, such as device in-
tegrity, quality of life, and cost effectiveness can be com-
pared with guidelines outlined below. Likewise, grading
schemes for reporting complications and their severity, al-
though primarily focused on endovascular treatment in this
report and prior standards documents,2,3 can be adapted
with little modification for open repair. Finally, when two
or more patient populations treated with open surgery and
endovascular approaches are compared, adjusting for case
severity mix, particularly with respect to comorbid medical
conditions, can be performed with schemes described else-
where.2,3
Quality of life and cost-effectiveness studies. The
benefit provided by new interventions must be weighed
against their expense. Therefore, studies designed to eval-
uate aortic endograft technology may include an assess-
ment of both the cost of this technology and the quality of
life of the treated patient. Examples of variables that should
be evaluated for the use of endografts with respect to open
surgery include hospital stay, mortality and morbidity, dis-
charge to home vs a skilled nursing facility or rehabilitation
facility, perioperative and long-term quality of life, return
to normal activity, need for reintervention, and psychologic
stress. Quality of life must be assessed frequently enough to
capture the earlier postoperative rise of endovascular repair
and also the later postoperative rise of open repair. For an
economic analysis, cost rather than charge data should be
gathered and analyzed and should include as many of the
total costs as possible, including preadmission imaging,
postimplantation surveillance, and late secondary proce-
dures. The costs of rehabilitation stays, skilled nursing
facility, outpatient visits, and reinterventions should be
captured. The cost of nonvascular reintervention (eg,
incisional complications such as wound infection, hernia, in-
tervention or hospitalization for bowel obstruction secondary
to adhesions, etc) should be captured for both EVAR and
open repair. In regional or national population-based eco-
nomic studies, investigators should consider the addi-
tional costs of endovascular intervention compared with
the costs and consequences of rupture without therapy for
patients who would not otherwise be candidates for open
surgery.INVESTIGATOR DISCLOSURE AND CONFLICT
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REFERENCES
1. Ahn SS, Rutherford RB, Johnston KW,May J, Veith FJ, Baker JD, et al.
Reporting standards for infrarenal endovascular abdominal aortic aneu-
rysm repair. Ad Hoc Committee for Standardized Reporting Practices
in Vascular Surgery of The Society for Vascular Surgery/International
Society for Cardiovascular Surgery. J Vasc Surg 1997;25:405-10.
2. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic aneu-
rysm repair. J Vasc Surg 2002;35:1048-60.
3. Chaikof EL, Fillinger MF, Matsumura JS, Rutherford RB, White GH,
Blankensteijn JD, et al. Identifying and grading factors that modify the
outcome of endovascular aortic aneurysm repair. J Vasc Surg 2002;35:
1061-6.
4. Crawford ES, Crawford JL, SafiHJ, Coselli JS,Hess KR, Brooks B, et al.
Thoracoabdominal aortic aneurysms: preoperative and intraoperative
factors determining immediate and long-term results of operations in
605 patients. J Vasc Surg 1986;3:389-404.
5. Safi HJ, Miller CC 3rd, Huynh TT, Estrera AL, Porat EE, Winnerkvist
AN, et al. Distal aortic perfusion and cerebrospinal fluid drainage for
thoracoabdominal and descending thoracic aortic repair: ten years of
organ protection. Ann Surg 2003;238:372-80; discussion 380-1.
6. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience
with 1509 patients undergoing thoracoabdominal aortic operations. J
Vasc Surg 1993;17:357-68; discussion 368-70.
7. Cambria RP. Thoracoabdominal aortic aneurysms. In: Rutherford
RB, ed. Vascular surgery. 5th ed. Philadelphia, PA: Saunders
Elsevier; 2000. p. 1303-25.
8. Upchurch GRJ, Patel HJ. Thoracic and thoracoabdominal aortic aneu-
rysms: evaluation and decision making. In: Cronenwett JL, Johnston
KW, eds. Rutherford’s vascular surgery. 7th ed. Philadelphia, PA:
Saunders Elsevier; 2010. p. 1490-1511.
9. Safi HJ, Huynh TT, Estrera AL, Miller CC, 3rd. Thoracoabdominal
aortic aneurysm. In: Rutherford RB, ed. Vascular surgery. 6th ed.
Philadelphia, PA: Saunders Elsevier; 2005. p. 2014-30.
10. Crawford ES. The diagnosis and management of aortic dissection.
JAMA 1990;264:2537-41.
11. Criado FJ, Clark NS, Barnatan MF. Stent graft repair in the aortic arch
and descending thoracic aorta: a 4-year experience. J Vasc Surg 2002;
36:1121-8.
12. Mitchell RS, Ishimaru S, Ehrlich MP, Iwase T, Lauterjung L, Shimono
T, et al. First International Summit on Thoracic Aortic Endografting:
roundtable on thoracic aortic dissection as an indication for endograft-
ing. J Endovasc Ther 2002;9(suppl 2):II98-105.
13. Buth J, Harris PL,Hobo R, van Eps R, Cuypers P, Duijm L, Tielbeek X.
Neurologic complications associated with endovascular repair of tho-
racic aortic pathology: Incidence and risk factors. a study from the
European Collaborators on Stent/Graft Techniques for Aortic Aneu-
rysm Repair (EUROSTAR) registry. J Vasc Surg 2007;46:1103-10;
discussion 1110-1.
14. Greenberg RK, LuQ, Roselli EE, Svensson LG,MoonMC,Hernandez
AV, et al. Contemporary analysis of descending thoracic and thoraco-
abdominal aneurysm repair: a comparison of endovascular and open
techniques. Circulation 2008;118:808-17.
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 4 Fillinger et al 103315. Singh-Ranger R, McArthur T, Corte MD, Lees W, Adiseshiah M. The
abdominal aortic aneurysm sac after endoluminal exclusion: a medium-
term morphologic follow-up based on volumetric technology. J Vasc
Surg 2000;31:490-500.
16. Wever JJ, Blankensteijn JD, Th MMWP, Eikelboom BC. Maximal
aneurysm diameter follow-up is inadequate after endovascular abdom-
inal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2000;20:177-82.
17. Fillinger M. Three-dimensional analysis of enlarging aneurysms after
endovascular abdominal aortic aneurysm repair in the Gore Excluder
Pivotal clinical trial. J Vasc Surg 2006;43:888-95.
18. Fillinger MF. Postoperative imaging after endovascular AAA repair.
Semin Vasc Surg 1999;12:327-38.
19. Dias NV, Ivancev K, Resch TA, Malina M, Sonesson B. Endoleaks after
endovascular aneurysm repair lead to nonuniform intra-aneurysm sac
pressure. J Vasc Surg 2007;46:197-203.
20. Jones JE, Atkins MD, Brewster DC, Chung TK, Kwolek CJ, LaMura-
glia GM, et al. Persistent type 2 endoleak after endovascular repair of
abdominal aortic aneurysm is associated with adverse late outcomes. J
Vasc Surg 2007;46:1-8.
21. Resch T, Ivancev K, Lindh M, Nyman U, Brunkwall J, Malina M, et al.
Persistent collateral perfusion of abdominal aortic aneurysm after endo-
vascular repair does not lead to progressive change in aneurysm diam-
eter. J Vasc Surg 1998;28:242-9.
22. Tarlov IM, Herz E. Spinal cord compression studies. IV. Outlook with
complete paralysis in man. Arch Neurol Psych. 1954;72:43-59.
23. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
24. Sacks D, Marinelli DL, Martin LG, Spies JB. Reporting standards for
clinical evaluation of new peripheral arterial revascularization devices. J
Vasc Interv Radiol 2003;14(9 Pt 2):S395-404.
25. Uniform requirements for manuscripts submitted to biomedical jour-
nals. International Committee ofMedical Journal Editors. JAMA 1997;
277:927-34.
26. Johnston KW, Rutherford RB. Disclosure of competition of interest. J
Vasc Surg 1999;30:200-2.
27. Johnston KW, Rutherford RB. Policy on declaring conditions of fund-
ing for research studies. J Vasc Surg 2002;35:197.
28. Fillinger MF. New imaging techniques in endovascular surgery. Surg
Clin North Am 1999;79:451-75.
29. Fillinger MF. Imaging of the thoracic and thoracoabdominal aorta.
Semin Vasc Surg 2000;13:247-63.
30. Ouriel K, Green RM, Donayre C, Shortell CK, Elliott J, DeWeese JA.
An evaluation of new methods of expressing aortic aneurysm size:
relationship to rupture. J Vasc Surg 1992;15:12-18; discussion 19-20.
31. Aarts NJ, Schurink GW, Schultze Kool LJ, Bode PJ, van Baalen JM,
Hermans J, et al. Abdominal aortic aneurysm measurements for endo-
vascular repair: intra- and interobserver variability of CTmeasurements.
Eur J Vasc Endovasc Surg 1999;18:475-80.
32. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher
CW, et al. Variability in measurement of abdominal aortic aneurysms.
Abdominal Aortic Aneurysm Detection and Management Veterans Ad-
ministration Cooperative Study Group. J Vasc Surg 1995;21:945-52.
33. Singh K, Jacobsen BK, Solberg S, Bonaa KH, Kumar S, Bajic R, et al.
Intra- and interobserver variability in the measurements of abdominal
aortic and common iliac artery diameter with computed tomography.
The Tromso study. Eur J Vasc Endovasc Surg 2003;25:399-407.
34. Harris P, Brennan J, Martin J, Gould D, Bakran A, Gilling-Smith G, et
al. Longitudinal aneurysm shrinkage following endovascular aortic an-
eurysm repair: a source of intermediate and late complications. J Endo-
vasc Surg 1999;6:11-6.
35. Greenberg RK, Haddad F, Svensson L, O’Neill S, Walker E, Lyden SP,
et al. Hybrid approaches to thoracic aortic aneurysms: the role of endovas-
cular elephant trunk completion. Circulation 2005;112:2619-26.36. O’Neill S, Greenberg RK, Resch T, Bathurst S, Fleming D, Kashyap V,
et al. An evaluation of centerline of flow measurement techniques to
assess migration after thoracic endovascular aneurysm repair. J Vasc
Surg 2006;43:1103-10.
37. Wyers MC, Fillinger MF, Schermerhorn ML, Powell RJ, Rzucidlo EM,
Walsh DB, et al. Endovascular repair of abdominal aortic aneurysm
without preoperative arteriography. J Vasc Surg 2003;38:730-8.
38. Beebe HG, Jackson T, Pigott JP. Aortic aneurysm morphology for
planning endovascular aortic grafts: limitations of conventional imaging
methods. J Endovasc Surg 1995;2:139-48.
39. Resch T, Ivancev K, Lindh M, Nirhov N, Nyman U, Lindblad B.
Abdominal aortic aneurysmmorphology in candidates for endovascular
repair evaluated with spiral computed tomography and digital subtrac-
tion angiography. J Endovasc Surg 1999;6:227-32.
40. Matsumura JS, Chaikof EL. Continued expansion of aortic necks after
endovascular repair of abdominal aortic aneurysms. EVT Investigators.
EndoVascular Technologies, Inc. J Vasc Surg 1998;28:422-30; discus-
sion 430-1.
41. Resch T, Ivancev K, Brunkwall J, Nirhov N, Malina M, Lindblad B.
Midterm changes in aortic aneurysm morphology after endovascular
repair. J Endovasc Ther 2000;7:279-85.
42. Figueroa CA, Taylor CA, Chiou AJ, Yeh V, Zarins CK. Magnitude and
direction of pulsatile displacement forces acting on thoracic aortic
endografts. J Endovasc Ther 2009;16:350-8.
43. White GH, Yu W, May J, Chaufour X, Stephen MS. Endoleak as a
complication of endoluminal grafting of abdominal aortic aneurysms:
classification, incidence, diagnosis, and management. J Endovasc Surg
1997;4:152-68.
44. White GH,May J, Waugh RC, Chaufour X, YuW. Type III and type IV
endoleak: toward a complete definition of blood flow in the sac after
endoluminal AAA repair. J Endovasc Surg 1998;5:305-9.
45. Schurink GW, Aarts NJ, Wilde J, van Baalen JM, Chuter TA, Schultze
Kool LJ, et al. Endoleakage after stent-graft treatment of abdominal
aneurysm: implications on pressure and imaging—an in vitro study. J
Vasc Surg 1998;28:234-41.
46. Alerci M, Oberson M, Fogliata A, Gallino A, Vock P, Wyttenbach R.
Prospective, intraindividual comparison of MRI versus MDCT for
endoleak detection after endovascular repair of abdominal aortic aneu-
rysms. Eur Radiol 2009;19:1223-31.
47. van der Laan MJ, Bartels LW, Viergever MA, Blankensteijn JD. Com-
puted tomography versus magnetic resonance imaging of endoleaks
after EVAR. Eur J Vasc Endovasc Surg 2006;32:361-5.
48. Cohen EI, Weinreb DB, Siegelbaum RH, Honig S, Marin M, Wein-
traub JL, Lookstein RA. Time-resolved MR angiography for the classi-
fication of endoleaks after endovascular aneurysm repair. J Magn Reson
Imaging 2008;27:500-3.
49. van Herwaarden JA, Muhs BE, Vincken KL, van Prehn J, Teutelink A,
Bartels LW, et al. Aortic compliance following EVAR and the influence
of different endografts: determination using dynamic MRA. J Endovasc
Ther 2006;13:406-14.
50. van Keulen JW, van Prehn J, Prokop M, Moll FL, van Herwaarden JA.
Dynamics of the aorta before and after endovascular aneurysm repair: a
systematic review. Eur J Vasc Endovasc Surg 2009;38:586-96.
51. Gilling-Smith GL,Martin J, Sudhindran S, GouldDA,McWilliams RG,
Bakran A, et al. Freedom from endoleak after endovascular aneurysm
repair does not equal treatment success. Eur J Vasc Endovasc Surg
2000;19:421-5.
Submitted Jul 10, 2010; accepted Jul 14, 2010.
Additional material for this article may be found online
at www.jvascsurg.org.
JOURNAL OF VASCULAR SURGERY
October 20101033.e1 Fillinger et alAPPENDIX. Methodology and reporting of anatomic
measurements, endoleak, and endograft configurations
METHODOLOGY AND REPORTING OF
ANATOMIC MEASUREMENTS
Methodology for measuring changes in aneurysm
diameter, volume, and length diameter. Aneurysm size
should be expressed as maximum diameter and should
include volume data if available. Modality, method, and
definitions should be clearly described, and comparisons
should only be made between identical methods of mea-
surement. Given the inherent tortuosity of much of the
thoracic aorta, the maximum aortic or aneurysm diameter
should be measured perpendicular (orthogonal) to the
central lumen line or the centerline of the vessel (which are
not identical in all cases due to asymmetrical thrombus,
plaque and/or dissection), using three-dimensional recon-
structions of computed tomographic (CT) or magnetic
resonance (MR) scan images. Because aneurysm cross sec-
tions may appear elliptical on axial images, the minor axis of
the ellipse (smaller diameter) is generally a closer approxi-
mation of true maximum aneurysm diameter if digital
images are not available for three dimensional reconstruc-
tion.28-30 The intraobserver and interobserver variability of
diameter measurements obtained from CT scan images
range between 2 and 5 mm or 5% and 15%.31-33 Therefore,
a diameter change of 5 mm or more is considered signifi-
cant. Blinding of observers and datasets are recommended
to minimize bias.
Volume. Total aortic volume or total aneurysm vol-
ume is defined as the volume within the native aortic wall,
and should be defined to begin and end at a reproducible
landmark, such as “from just distal to the left subclavian
artery origin to the first CT slice containing the celiac artery
origin”. Lumen volume is defined as the volume circum-
scribed by the endograft and the true lumen in the case of
dissection, while nonlumen volume is comprised of throm-
bus external to the prosthesis (if present), endoleak, and
false lumen of a dissection if present. Endograft dilatation
may be associated with an increase in lumen volume, while
reduction in aneurysm size is principally related to a de-
crease in nonlumen volume. Stent graft expansion may
obscure changes of the sac when TEVAR is used to treat
small aneurysms or pseudoaneurysms, therefore extralumi-
nal sac volume may be used to better evaluate sac behavior
over time. The term complete aneurysm resolution may be
used if the nonlumen aneurysm volume is less than 10% of
the original nonlumen volume measured after endograft
implantation. The intraobserver and interobserver variabil-
ity for volume measurements have ranged between 3% and
8%, with a volume change of 5% or 10% typically considered
significant.2,3,15-18 A percentage may not be ideal for small
aneurysms, and the threshold validation range should be
known, along with the minimum detectable size change for
small-volume aneurysms. Ideally the interobserver variabil-
ity and minimum detectable size change will be known and
stated within the report. Blinding of observers and datasets
are recommended to minimize bias.Length. Alterations in aortic length have been noted.
Shortening has occurred in the setting of a reduced aneu-
rysm size and may be associated with morphologic changes
in the endovascular prosthesis such as endograft buckling,
kinking, and component dislocation.34 Aortic lengthening
may occur in the presence of a pre-existing aortic prosthesis
such as an aortic arch repair, following endovascular com-
pletion of elephant trunk graft repairs, and in the setting of
conventional treatment with an endovascular stent
graft.35,36 Thus aortic length is recommended to be mea-
sured between two reproducible endpoints, such as the
subclavian and celiac artery, along the central lumen line or
vessel centerline, as depicted in three-dimensional recon-
structions from CT or MR scan images.2,3,36,37 Aortic
length should also be measured from the proximal repro-
ducible endpoint to the proximal endograft (eg, left carotid
or subclavian to top-of-graft) and from the distal reproduc-
ible endpoint to the distal endograft (eg, celiac to distal
end-of-graft). Temporal comparisons of length measure-
ments should occur only when the same method for mea-
surement is used for each length calculation. In the absence
of three-dimensional reconstruction, aneurysm length is
underestimated as determined from axial CT scan imag-
es.38,39 Axial or straight-line measurements may be of
limited value only as an adjunct to centerline measurements
in an effort to describe complex three-dimensional relation-
ships (eg, tortuosity index).3 It should be noted that limi-
tations exist for angiography performed with a calibrated
marker catheter, and this is not the preferred method for
reporting, especially since it does not lend itself to serial
follow-up measurements.
Migration measurements
Image acquisition and reconstruction. Imaging
studies are recommended at discharge or at least within 1
month of the procedure, 6 months postoperative, 12 months
postoperative and yearly thereafter. High-resolution contrast
enhanced spiral CT studies of the chest and abdomen are
required to properly assess thoracic device stability. For anal-
ysis of migration and other morphologic changes, images
should be acquired using a collimation appropriate to allow
for reconstructions with a longitudinal (axial or “Z”) resolu-
tion of 3mmor better, and have a pixel size (X-Y) of 1mmor
less. The collimation or beam thickness should not be con-
fused with the reconstruction interval (reformat interval). A
collimation or beam thickness of 1.5 mm or less is preferred,
which requires a multi-detector row CT scanner. A slice
reconstruction interval or reformat interval of 0.75-1 mm is
preferred for optimal resolution of branches, smaller vascula-
ture, and aneurysm shape and size. The inherent tortuosity of
the thoracic aorta precludes two-dimensional image analyses
to conduct migration assessment, other than gross device
movement. Thus, digital data coupledwith three-dimensional
analysis tools aremandatory for this aspect of device reporting.
Initial screen for migration. A centerline of flow or
central lumen line (CLL) pathway should be generated
using a validated technique (automated, semi-automated
or manual) to identify the center of the contrast-enhanced
lumen. Images orthogonal to the CLL are used to identify
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common carotid artery) and distal reference point (CA,
celiac artery). An intermediate stable anatomic landmark in
closer proximity to the device may also be used (eg, a
readily identified calcified plaque). The CLL distance be-
tween the LCCA and CA is assessed to determine the
stability of the thoracic aortic length. If the length of the
thoracic aorta is noted to be temporally stable, then addi-
tional CLL measurements can be calculated from these
reference landmarks as described below. If the length is
noted to be unstable or cannot be calculated, then an
alternative migration assessment with local landmarks
should occur (see next section). Assuming aortic length
stability, the CLL distances are calculated from the LCCA
or proximal anatomic landmark to the proximal stent tip
(PST, most proximal visualization of the stent) and proxi-
mal stent circumferential (PSC, most proximal point where
the full circumference of the stent is first seen). Similar
measurements are taken from the CA or distal anatomic
landmark to the distal stent tip (DST, most distal visualiza-
tion of the stent) and distal stent circumferential (DSC,
most distal point where the full circumference of the stent is
first seen) appearance. A CLL length change in excess of
10mm of the PST and PSC from the proximal anatomic
landmark implies proximal stent migration. CLL length
changes in excess of 10mm of the PST or PSC (but not
both) from the LCCA implies angulation of the proximal
stent. CLL lengthmeasurement changes in excess of 10mm
between the CA and DST and DSC implies migration of
the distal stent, while CLL length alterations greater than
10mm to either the DST or DSC (but not both) implies
angulation of the distal stent. Patients that meet any of the
screening test endpoints listed above including migration
or angulation of the proximal or distal stent should then
undergo migration adjudication analysis.
Migration adjudication analysis. This analysis re-
quires a visual assessment of the reconstructed aortic seg-
ment fromwhich a specific fixed landmark (fiducial, or fixed
point of comparison) must be identified within the aortic
wall (eg, calcifications) or attached to the aorta or surgically
implanted aortic prostheses (eg, hemaclips), in close prox-
imity to the proximal or distal stent graft. If aortic land-
marks are not present, an adjacent bony landmark may be
used, but requires axial CT reformats in conjunction with a
three-dimensional reconstruction in order to perform the
evaluation. Distance measurements of the PST and PSC or
DST and DSC to landmarks closer than the fixed arterial
branches (LCCA or CA) will help to differentiate between
global aortic length changes from devicemovement relative
to the initial implantation site. Movement in excess of 10
mm from these local proximal landmarks to the PST and
PSC, or distal landmarks to the DST and DSC implies
device migration.
Methodology for measuring changes in neck di-
mension. Long-term aneurysm exclusion and device sta-
bilization is dependent on the maintenance of an effective
attachment and seal between the endograft and the host
aorta. Therefore, dilatation of the aorta at the site or sitesintended for primary endograft fixation may lead to treat-
ment failure either with device migration or via the occur-
rence of a new endoleak with aneurysm expansion.17,40,41
Both diameter and cross-sectional area of the aortic
neck at the sites intended for sealing or graft attachment are
reportable parameters, and such measurements should be
made using images reformatted to assess diameters perpen-
dicular to the lumen or vessel centerline. In the rare in-
stance that multiplanar CT reformats and 3-D reconstruc-
tion are not available, the smallest diameter (minor axis of
the elliptical cross section) is generally the best approxima-
tion of the actual neck diameter.2,3,40 This statement is not
universally true, however, and assessment with axial images
should be avoided. Notably, the outer perimeter of the
aortic wall should be used as the reference point for all
measurements. If the lumen diameter is the focus of the
study, it may be reported in addition to the corresponding
outer wall measurement. Modality, method, and defini-
tions should be clearly described, and comparisons should
only be made between identical sources (CT to CT, MR to
MR).
Changes in the dimension of aortic branch arteries.
Progressive angulation of the aortoiliac segment leading to
distortions of the endograft can accompany reductions in
aneurysm size for thoracic and thoracoabdominal aortic
aneurysms. This may result in endograft disruption, steno-
sis, and branch or limb occlusion for hybrid de-branching
limbs and for branched and fenestrated endografts. Alter-
ations in branch artery angulation and size after endovas-
cular grafting and the consequent responses of the prosthe-
sis may be important determinants of outcome. At the time
of this report, there are no standards for de-branching
procedures, branched and fenestrated endografts. Reports
directed at characterizing outcomes of interest for these
procedures are encouraged, following general principles
outlined for TEVAR thus far. Further potential consider-
ations follow, pending more data for future reporting stan-
dards directed specifically at these issues.
Methodology for measuring changes in branch ar-
tery diameter and tortuosity. Three-dimensional image
analysis with appropriate anatomic referencing is recom-
mended for accurate determination of branch artery angu-
lation. Measures derived from plain abdominal x-rays are
discouraged, as variations in position, angulation, and
equipment may have a significant impact on the reproduc-
ibility of derived measures. Definitions and categorization
of iliac tortuosity and angulation have been detailed else-
where, as have potential model methods for describing
visceral branch arteries.3,42
Methodology for reporting sequential changes in
aortoiliac morphology. After placement of an endovas-
cular prosthesis, the local biomechanical and hemodynamic
environments of the native aorta are altered. As a conse-
quence, dynamic changes in morphology of the aorta and
branch arteries can be observed over time. The rate, mag-
nitude, and direction of this response will be influenced by
properties inherent to the chosen device and host aorta.
Capturing the time course and the direction of these asso-
JOURNAL OF VASCULAR SURGERY
October 20101033.e3 Fillinger et alciated morphologic changes may be a direction for future
research.
ENDOLEAK
Endoleak is defined by the persistence of blood flow
outside the lumen of the endoluminal graft but within the
aneurysm sac, most likely resulting from an incomplete
exclusion of the aneurysm from the circulation, as deter-
mined by an imaging study.43 To simplify the following
discussion, the term “aneurysm” will be understood to
imply any contained segment of aortic pathology that may
dilate following endovascular repair. This definition is not
directed at primary dissection, as continued perfusion of
the false lumen is a special circumstance that may not be
directly analogous to endoleak. For example, there may be
a difference in outcome for proximal or thoracic false lumen
thrombosis versus distal or abdominal false lumen throm-
bosis. The status of the false lumen is an area for potential
clinical investigation, and may be addressed in a set of
reporting standards directed specifically for dissection.
Classification of endoleak. An endoleak can be clas-
sified according to time of occurrence relative to the oper-
ative procedure and site of origin.2,43,44 An endoleak first
observed during the perioperative (30 days) period is
defined as a primary endoleak, and if the initial detection
occurs more than 30 days following the procedure (or on
the second postoperative study) it is termed a secondary
endoleak.2,43,44 The reappearance of an endoleak either
after spontaneous resolution or after an intervention that
was considered successful is defined as a recurrent endoleak.
Further categorization requires precise information regard-
ing the course of blood flow into the aneurysm sac. The
definitions of endoleak types are well known and can be
summarized as (Table VI):
Type I:
A – Leak at the proximal graft attachment site
B – Leak at the distal graft attachment site
C – Leak around a branch occluding plug (eg, oc-
cluding a subclavian artery arising from the aneurysm sac to
prevent Type II branch flow into the sac)
Type II: retrograde flow from branch arteries arising
from the excluded segment
Type III:
A – Modular Disconnect
B – Fabric tear
Type IV: Flow through porous fabric (generally re-
solves within a short time period, typically less than 24
hours)
Type V: No detected endoleak, but aneurysm expan-
sion (thus presumed failure to detect the endoleak or
presumed pressure transmission through thrombus with-
out bloodflow)
Methodology for measuring the presence, source,
magnitude, and physiologic significance of endoleak
and endotension. Endoleak detection is most commonly
performed using a contrast-enhanced CT scan, which may
require comparison to a noncontrast imaging study. CT
imaging may fail to identify an endoleak if delayed-contrastimages are not obtained after infusion of contrast medi-
um.45 MR imaging, especially delayed imaging with gado-
linium or blood-pool contrast enhancement, has been re-
ported to be particularly sensitive and useful as a means of
detecting endoleak.46,47 The sensitivity and specificity of
available imaging methods for endoleak detection have not
been characterized well, in part because some stent grafts
are not MR-compatible. Dynamic CT or dynamic MR can
quantify aneurysm morphology over time, and have been
suggested as another means to evaluate for potential sac
pressurization.48-50 Reports involving dynamic CT or MR
should describe the methods in detail, including slice thick-
ness, gating methods, volume covered, and radiation dose.
Although intra-sac pressure may approach systemic ar-
terial pressure in the presence of an endoleak, some type II
endoleaks have been associated with shrinking aneurysms
and intrasac pressures that are substantially less than sys-
temic values.51 If pressure measurement techniques are
utilized, details regarding the specific method by which the
measurements were obtained as well as their relationship to
systemic pressures should be provided.
Characterizing the frequency of endoleak in a study
population during a defined observation period. Re-
ports should include the prevalence (%) of endoleak over
the duration of the implant period. Endoleaks must be
stratified by:
1) time of endoleak occurrence (primary, secondary,
recurrent);
2) site of endoleak origin;
3) the proportion of patients with an endoleak and
confirmed aneurysm expansion; and
4) the proportion of patients without detectable en-
doleak with demonstrable aneurysm expansion (ie,
possible endotension).
The number of patients available for analysis must be
specified at each time point.
In characterizing the absence of endoleak at any time
during a study period, life table or Kaplan-Meier analysis
should be used for data presentation, as in “freedom
from endoleak or endoleak-free survival”. In order to
allow comparison of studies with pre-discharge studies
and studies only at 30 days, life tables for endoleak may
start at the 1 month post-operative CT scan. In this
regard, primary, assisted primary, and secondary “ab-
sence of endoleak” curves, which are distinguished on
the basis of whether or not a secondary surgical or
catheter-based intervention was performed, can be used
to assess the role of endoleak-directed intervention, but
these should alter the life table whether within the first
30 days or not. In this manner, early interventions are
not missed or under-reported.
CATEGORIZATION OF ENDOGRAFT
CONFIGURATIONS AND COMPONENTS
Precise description of the configuration, modularity,
fabric, support, and fixation structures of the endograft
system should be provided, if not detailed elsewhere, in
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devices, and maneuvers. Recommendations regarding uni-
form reporting of device configuration and components are
outlined in Table III.
Configuration: Location, length, modularity, and di-
ameter
Location and zones of attachment. The location of
attachment relates to the risk and complexity of the proce-
dure as well as component selection and stresses on the
devices. A system is already in place to describe the proximal
zones of attachment, originally proposed to describe the
ascending aorta, arch and proximal descending aorta
(Zones 0-4).11,12 Reporting the proximal attachment
Zone is particularly important when reporting neurologic
outcomes, as cerebrovascular outcomes appear to be re-
lated to the proximal attachment site Zone.11,13 Both the
proximal and distal attachment zone likely affect patient
risk, device selection, complexity of the procedure and
stresses on devices,14 so an extended zone system is de-
scribed here that allows for a complete description of both
proximal and distal attachment site by zone. See Fig 1 in the
on-line appendix in addition to the following text.
Proximal attachment zone. Proximal endograft at-
tachment site, defining the proximal edge of covered en-
dograft. Zone 0 the proximal edge of the covered en-
dograft is proximal to the innominate artery origin; 1
distal to the innominate but proximal to the left common
carotid artery origin; 2 distal to the left common carotid
but proximal to the subclavian artery; 3 within 2 cm of
the left subclavian artery without covering it; 4proximal
extent of the endograft is2 cm distal to the left subclavian
artery and ends within the proximal half of the descending
thoracic aorta (T6 approximating the mid-point of the
descending thoracic aorta); 5 starts in distal half of the
descending thoracic aorta but proximal to the celiac artery;
6celiac origin to top of SMA; 7SMA origin, suprarenal
aorta. For devices with bare stents, it may be useful to
differentiate the covered and noncovered endpoint.
Distal attachment zone. Distal endograft attachment
site, defining the distal edge of covered endograft. Zones
4distal extent of the endograft is 2 cm distal to the left
subclavian artery and within the proximal half of the de-
scending thoracic aorta (T6 approximating the mid-point
of the descending thoracic aorta); 5 ends in the distal half
of the descending thoracic aorta but proximal to the celiac
artery; 6covers celiac, ends proximal to SMA; 7covers
SMA, ends proximal to renal arteries; 8covers at least 1
renal artery; 9infrarenal; 10 common iliac; 11external
iliac. For iliac arteries, the zone can be reported separately
or by the most distal site (eg, if one side ends in the
common iliac artery and the other ends in the external iliac
artery, use zone 11). For devices with bare stents, it is useful
to differentiate the covered and noncovered end point.
For extensive repairs, the status of both internal iliac
arteries should be reported (patent, chronically occluded,
coiled/covered by the repair). Note also that by using a
definition that T6 approximates the mid-point of the de-
scending thoracic aorta, the “zone” system can be used tocorrelate with the traditional Type I-IV Crawford-type
classification system, but with more precision.
Alternatives. Alternatively, the distal attachment loca-
tion may be reported relative to the anatomic segment,
namely descending thoracic aorta (proximal half, distal
half), the visceral aortic segment (describing the branches
that are covered), the infrarenal aorta, the common iliac or
external iliac arteries. For extensive repairs, the status of the
internal iliac arteries should be reported (patent, chroni-
cally occluded, coiled/covered by the repair). In general, it
is best to be as specific as possible when reporting anatomic
coverage (zones of attachment) or use more traditional
classifications (Crawford classifications).
Length of coverage. Length of coverage is a risk
factor for paraplegia, and is thus of interest in TEVAR
reports. Length of coverage may be recorded in terms of
absolute length (cm) or the proportion of coverage of the
descending thoracic aorta. For example, the coverage may
be described as less than one-third of the descending tho-
racic aorta, one-third to two-thirds, or greater than two-
thirds of the descending thoracic aorta. Beyond such de-
scriptions, the start and endpoints using the Zone
designation (see above) is also a potential method to deter-
mine the length of coverage. The best method to report
length of coverage is not yet determined, but one of these
methods should be used.
Modularity. Endografts should be categorized as
comprised of a single endograft or modular components,
which are assembled in situ within the vasculature of the
patient. Modular grafts must have overlapping junctions
between components. Any methods utilized to enhance or
alter the attachment of one component to another should
be reported (eg, staples, balloon-expandable stents, etc). If
a standard method of overlapping is used (eg, a minimum
length in cm or always overlapping devices completely
within the sac), it should be reported.
Diameter. When the diameter of the graft is reported,
the largest and smallest diameters of the aortic graft(s) may
be of interest. Such reports should describe whether the
device is straight or tapered (in which case both the largest
and smallest diameters are reported) and whether multiple
devices are used (in which case the various aortic devices
may have a range of sizes). In such cases the largest and
smallest devices for the individual repair may be described,
or a standard taper configuration may be reported (eg, 4
mm from top to bottom) or a standard diameter change
between components may be described (eg, no more than
4 mm difference between components).
Configuration: Branch treatments including branched
endografts. The newest and most complex issue in report-
ing TEVAR stent graft configuration is for branch vessel
treatment. The aortic stent graft configuration may be
modified in a number of ways to treat aortic branch vessels.
The term “scallop” refers to a portion of aortic graft mate-
rial removed to accommodate an aortic branch at the
proximal or distal end of the aortic repair, thus allowing
some fabric to extend further proximally or distally than a
simple cylindrical configuration would allow. The term
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presence of openings purposely created within the en-
dograft to allow perfusion of visceral or brachiocephalic
arteries in the region otherwise covered by the aortic en-
dograft. If uncovered stents are placed within fenestrations,
the frequency should be noted and designated by a term
such as “stented fenestrations”. If a stent graft is placed
within a fenestration, but not required for sealing, the
proper term would still be stented fenestration. Thus, the
prefix “branched” is only used for aneurysms that involve a
target vessel whereby the use of mating stent grafts are
required to form a seal. The prefix “branched” is used to
indicate the presence of stent graft side-arms intended to
connect the primary aortic endograft to visceral, renal, or
brachiocephalic arteries in the region otherwise covered by
the aortic endograft. The implication is that a stent graft
branch is required for sealing across a gap between the
primary aortic endograft and the target visceral or arch
vessel (ie, a fenestration or stented fenestration would allow
flow or pressurization of the aneurysm sac). A “fenestrated
branch” seals into a fenestration which has been reinforced
to allow sealing, and a “side-arm branch” implies a side-arm
has been sewn onto the aortic stent graft component to
allow sealing. The type of branch should be reported, as
well as whether the branch is oriented antegrade or retro-
grade. For branches and fenestrations, the vessels intended
to receive scallops, fenestrations, stented fenestrations or
stent grafts should be described, as well as the total number
of stent grafts or stents required.
Other treatments for aortic branches may affect the
primary aortic stent graft(s). As such, they must be re-
ported, and the definition is included with graft configura-
tion even though the treatment may not technically modify
the primary aortic endograft configuration. Branch treat-
ments include debranching of the visceral or arch vessels.
De-branching is defined as a procedure in which a surgical
bypass is performed to originate perfusion of the aortic
branch artery from a location that will not be covered by the
intended aortic stent graft (eg, iliac-renal bypass, carotid-
subclavian bypass). The other commonly described branch
treatment is the placement of a stent or stent graft in an
aortic branch artery that is covered or partially covered by
the aortic stent graft, typically referred to as the “chimney”
or “snorkel” technique. With these treatments, the report
should include the number and type of stents, stent grafts
or grafts utilized, and whether the treatment was planned
or unplanned.
Endograft fabric. The nature of the graft material
should be identified. For example, the material may be
expanded polytetrafluoroethylene, knitted or woven
polyester fabric, some other material, or combinationthereof. If a change in fabric composition occurs over the
study period, the “generation” of the fabric should be
noted.
Support system. For the initial report of a new device,
the nature of the support system of the device also should
be defined. Reports should state whether the system fully or
partially supports the graft, whether it is balloon expand-
able or self-expanding, luminal or abluminal in relation to
the fabric, and whether the supporting framework is fixed
to the graft with stitches or otherwise incorporated within
the graft. Likewise, the geometric configuration and the
material composition of the metallic stent framework
should be specified. Nonstandard alloys should be de-
scribed. Subsequent reports may reference the initial report
of the device structure, but must note any modifications of
the device.
Fixation components and techniques. Reports
should specify whether graft fixation is achieved with a
component that is an integral part of the support skele-
ton or a separate or unique element of the endograft
system. The geometric configuration of these compo-
nents should be described, including whether hooks,
barbs, screws, pins, scales, or other means are used and
whether fixation is to be achieved with balloon or self-
expanding stents or by a means separate from endograft
deployment. Finally, the intended placement of a fixa-
tion system, proximal or distal to vessel orifices (eg,
subclavian artery) should be noted.
Endograft extensions and intraluminal stents. The
nature of adjunctive devices to assure proper fixation,
sealing, patency, and positioning of the endograft should
be described. For example, reports should include details
of graft extensions and the use of adjunctive intraluminal
balloon expandable or self-expanding stents or stent
grafts, unplanned stent graft components of another
manufacturer, extensions that would not be typical of the
device, and unplanned extensions.
Graft sizing relative to the native aorta. The
amount of graft over-sizing relative to the host artery
diameter at the intended fixation sites should be re-
ported, because this may affect attachment and sealing.
The degree of oversizing should be reported as an abso-
lute number and/or as a range and average percent of
oversizing. It should be specified as to whether oversiz-
ing is relative to the vessel lumen or to the outer vessel
wall. If over-sizing is reported relative to the lumen, the
report must specify the acceptable threshold of throm-
bus, noncalcified plaque or calcified plaque in terms of
both thickness (mm) and circumference (as a percentage
of the total circumference).
